Oncotype Dx Breast Recurrence Score
The only genomic test proven to predict a patient’s individual benefit from chemotherapy. For patients with early-stage, ER-positive, HER2-negative, node negative, and node-positive (1-3) breast cancer, the Oncotype DX Breast Recurrence Score quantifies the risk of distant recurrence and the likelihood of chemotherapy benefit.
The Breast Recurrence Score® assay is one of the most extensively studied genomic tests available for breast cancer patients today, with prospective clinical trials and outcome data gathered from more than 100,000 patients in more than 150 publications, providing the highest level of evidence supporting the test’s clinical utility.
The Breast Recurrence Score test is the only validated genomic test for breast cancer, which provides two key answers for both lymph node-negative and node-positive early-stage breast cancer patients:
● The test predicts whether a woman will benefit from chemotherapy.
● It also provides a percent likelihood of the cancer returning after appropriate hormone therapy is taken.
read More